Sobi Revises 2025 Outlook Following Strong Q3 Performance

Swedish Orphan Biovitrum AB ( (SE:SOBI) ) has shared an announcement.

Sobi has revised its full-year outlook for 2025, anticipating revenue growth in the low double digits and an adjusted EBITA margin in the mid-to-high 30s percentage. This adjustment follows a strong Q3 performance, with a 21% revenue increase driven by products like Altuvoct, Doptelet, and Gamifant, and disciplined cost control. Additionally, Sobi recorded a non-cash impairment charge for Vonjo but continues to see it as a long-term growth driver. The company also announced the approval of Tryngolza for familial chylomicronaemia syndrome in Europe, highlighting a significant market potential.

The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK370.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.

More about Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB (Sobi) is a biopharmaceutical company based in Stockholm, Sweden, specializing in the development and commercialization of treatments for rare diseases. The company focuses on delivering innovative therapies, particularly in the areas of hematology, immunology, and specialty care, with a significant market presence in Europe and other international markets.

YTD Price Performance: -1.83%

Average Trading Volume: 313,488

Technical Sentiment Signal: Strong Buy

Current Market Cap: SEK107.5B

Find detailed analytics on SOBI stock on TipRanks’ Stock Analysis page.